Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.

scientific article published on 10 November 2017

Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41598-017-15492-5
P932PMC publication ID5681687
P698PubMed publication ID29127384

P50authorHawk KimQ57840679
Yunsuk ChoiQ87433063
Jae-Cheol JoQ89221268
P2093author name stringYoung Joo Min
Sook-Kyoung Heo
Eui-Kyu Noh
Yoo Kyung Jeong
Jin Ho Baek
SuJin Koh
Jeong Yi Kim
P2860cites workPrognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic ReviewQ28067339
Genomic organization of the human c-kit gene: evolution of the receptor tyrosine kinase subclass IIIQ28186462
Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemiaQ28271726
Targeting the dynamic HSP90 complex in cancerQ28288602
Targeting heat shock proteins in cancerQ28298397
Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacityQ28539582
Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia CellsQ28548235
Molecular mechanism and physiological functions of clathrin-mediated endocytosisQ29615660
Dynasore, a cell-permeable inhibitor of dynaminQ29619881
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blastsQ32061790
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitorsQ33414445
Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.Q33848888
Heat shock protein 90 as a molecular target for cancer therapeuticsQ35099516
High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemiaQ35361598
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaQ35528633
The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabineQ35673943
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionQ35760845
Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cellsQ35786902
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.Q35952396
The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agentsQ37141899
Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogeneticsQ37240557
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemiaQ37386171
Targeting HSP90 for cancer therapyQ37463739
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implicationsQ37827283
The therapeutic target Hsp90 and cancer hallmarksQ38037753
Therapeutic targeting of c-KIT in cancerQ38057806
Ganetespib and HSP90: translating preclinical hypotheses into clinical promiseQ38189961
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancerQ38648408
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationQ38712298
Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors.Q38754508
Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of CancerQ38788166
Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemiaQ38989476
Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cellsQ39033189
Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic LeukaemiaQ39061903
Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation.Q39245467
Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemiasQ39966770
Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemiaQ40719234
Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cellsQ42970606
Inhibition of c-Kit by tyrosine kinase inhibitorsQ43175180
Dasatinib promotes ATRA-induced differentiation of AML cellsQ43208673
The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cellsQ46614261
Radotinib induces high cytotoxicity in c-KIT positive acute myeloid leukemia cellsQ47836202
Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors.Q51068076
A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer.Q51638544
HEL Cells: A New Human Erythroleukemia Cell Line with Spontaneous and Induced Globin ExpressionQ52831182
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targetsQ55115709
Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cellsQ67704489
Human erythroleukemia cell line (HEL) undergoes a drastic macrophage-like shift with TPAQ70157088
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectacute myeloid leukemiaQ264118
dasatinibQ419940
radotinibQ15269680
dasatinib monohydrateQ27139135
P304page(s)15278
P577publication date2017-11-10
P1433published inScientific ReportsQ2261792
P1476titleTargeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death
P478volume7